Type-1 diabetes (T1D) is a chronic metabolic autoimmune disease where the patient's immune system destroys insulin-producing β-cells in the islet of Langerhans. The current treatment option is through frequent administration of exogenous insulin, where the patients must closely monitor the dosage. Patients often need islet transplantation when the β-cell destruction worsens, and the body cannot utilize exogenously administrated insulin. Islet transplantation is a form of cell therapy that could restore endogenous insulin production. However, this method has several drawbacks, including low survival of functional islets and allograft tissue immunogenicity. A recently emerging tissue engineering approach can offer a possible solution to address the limitations of islet transplantation. A 3D structure fabricated by simultaneously printing various cell types could improve the survival and function of islet grafts by providing revascularization and immune protection.
This project foc
NSW is home to 4 of Australia’s top 10 universities, many of whom feature in the top 100 universities in the world and is also home to 37 per cent of the Australia’s.
The Australian state of New South Wales (NSW), home to the city of Sydney, highlighted its world-class health, medtech and R&D ecosystem at a VIP dinner event held at the Australia Pavilion at Expo 2020 Dubai.
Investigational magnetic device shrinks glioblastoma in first-in-world human test
Houston Methodist Neurological Institute researchers from the department of neurosurgery shrunk a deadly glioblastoma tumor by more than a third using a helmet generating a noninvasive oscillating magnetic field that the patient wore on his head while administering the therapy in his own home. The 53-year-old patient died from an unrelated injury about a month into the treatment, but during that short time, 31% of the tumor mass disappeared. The autopsy of his brain confirmed the rapid response to the treatment.
“Thanks to the courage of this patient and his family, we were able to test and verify the potential effectiveness of the first noninvasive therapy for glioblastoma in the world,” said David S. Baskin, M.D., FACS, FAANS, corresponding author and director of the Kenneth R. Peak Center for Brain and Pituitary Tumor Treatment in the Department of Neurosurgery at Houston Methodist. “The fa